HCW Biologics Inc. (HCWB)Healthcare | Biotechnology | Miramar, United States | NasdaqCM
3.43 USD
+0.26
(8.202%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.29 -0.14 (-0.140%) ⇩ (Aug. 28, 2026, 7:35 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:13 a.m. EDT
The immediate outlook is severely clouded by a relentless multi-year price collapse and a precarious balance sheet. While the company recently secured a $4 million PIPE investment and boasts impressive gross margins, the stock has lost nearly 98% of its value over the last four years, with four consecutive years of negative annual returns. This structural deterioration suggests the market has priced out the business quality entirely, likely due to the massive debt load ($6.5M) against minimal cash reserves ($1.2M) and a current ratio of just 0.086. The recent price action shows a sharp decline from August highs, trading well below the 50-day and 200-day moving averages, indicating strong downward momentum. With no dividend history and a forward P/E that is negative due to losses, there is no safety net for investors. The high beta amplifies volatility, making this a high-risk speculative vehicle rather than an investment opportunity. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.842439 |
| AutoETS | 0.842444 |
| MSTL | 0.902262 |
| AutoTheta | 1.354047 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 22% |
| H-stat | 9.87 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.459 |
| Excess Kurtosis | -0.87 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 88.337 |
| Revenue per Share | 8.534 |
| Market Cap | 6,298,591 |
| Forward P/E | -6.24 |
| Beta | 2.36 |
| Profit Margins | -83.05% |
| Website | https://www.hcwbiologics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.90124613 |
| Address1 | 2,929 North Commerce Parkway |
| All Time High | 1,866.0 |
| All Time Low | 1.5 |
| Ask | 3.9 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 266,460 |
| Average Daily Volume3 Month | 143,603 |
| Average Volume | 143,603 |
| Average Volume10Days | 266,460 |
| Beta | 2.364 |
| Bid | 2.45 |
| Bid Size | 1 |
| Book Value | 4.592 |
| City | Miramar |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.43 |
| Current Ratio | 0.061 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.43 |
| Day Low | 3.0 |
| Debt To Equity | 88.337 |
| Display Name | HCW Biologics |
| Ebitda | -5,584,538 |
| Ebitda Margins | -0.83088994 |
| Enterprise To Ebitda | -2.17 |
| Enterprise To Revenue | 1.803 |
| Enterprise Value | 12,118,628 |
| Eps Forward | -0.55 |
| Eps Trailing Twelve Months | -17.93 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 954 842 2037 |
| Fifty Day Average | 3.87542 |
| Fifty Day Average Change | -0.44542003 |
| Fifty Day Average Change Percent | -0.114934646 |
| Fifty Two Week Change Percent | -90.12461 |
| Fifty Two Week High | 36.648 |
| Fifty Two Week High Change | -33.218 |
| Fifty Two Week High Change Percent | -0.9064069 |
| Fifty Two Week Low | 1.5 |
| Fifty Two Week Low Change | 1.9300001 |
| Fifty Two Week Low Change Percent | 1.2866668 |
| Fifty Two Week Range | 1.5 - 36.648 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,626,787,800,000 |
| Float Shares | 1,069,787 |
| Forward Eps | -0.55 |
| Forward P E | -6.2363634 |
| Free Cashflow | -11,661,168 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 35 |
| Fullday Change | 0.26 |
| Fullday Change Percent | 8.20189 |
| Fullday Price | 3.29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.95914 |
| Gross Profits | 6,446,566 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09722 |
| Held Percent Institutions | 0.09026 |
| Implied Shares Outstanding | 1,836,324 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-20 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,782,777,600 |
| Last Split Factor | 1:6 |
| Long Business Summary | HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida. |
| Long Name | HCW Biologics Inc. |
| Market | us_market |
| Market Cap | 6,298,591 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_628452149 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -21,410,162 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,821,147 |
| Number Of Analyst Opinions | 1 |
| Open | 3.2 |
| Operating Cashflow | -12,136,822 |
| Operating Margins | -23.35573 |
| Payout Ratio | 0.0 |
| Phone | 954 842 2024 |
| Post Market Change | -0.1400001 |
| Post Market Change Percent | -4.0816355 |
| Post Market Price | 3.29 |
| Post Market Time | 1,787,960,115 |
| Previous Close | 3.17 |
| Price Hint | 4 |
| Price To Book | 0.7469512 |
| Price To Sales Trailing12 Months | 0.9371249 |
| Profit Margins | -0.83049005 |
| Quick Ratio | 0.041 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.26 |
| Regular Market Change Percent | 8.20189 |
| Regular Market Day High | 3.43 |
| Regular Market Day Low | 3.0 |
| Regular Market Day Range | 3.0 - 3.43 |
| Regular Market Open | 3.2 |
| Regular Market Previous Close | 3.17 |
| Regular Market Price | 3.43 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 117,134 |
| Return On Assets | -0.13885 |
| Return On Equity | -1.51359 |
| Revenue Growth | 19.697 |
| Revenue Per Share | 8.534 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,836,324 |
| Shares Percent Shares Out | 0.0078 |
| Shares Short | 14,348 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 29,960 |
| Short Name | HCW Biologics Inc. |
| Short Percent Of Float | 0.0082 |
| Short Ratio | 0.2 |
| Source Interval | 15 |
| State | FL |
| Symbol | HCWB |
| Target High Price | 29.99999 |
| Target Low Price | 29.99999 |
| Target Mean Price | 29.99999 |
| Target Median Price | 29.99999 |
| Total Cash | 741,324 |
| Total Cash Per Share | 0.404 |
| Total Debt | 6,561,361 |
| Total Revenue | 6,721,186 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -17.93 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.161945 |
| Two Hundred Day Average Change | -2.7319448 |
| Two Hundred Day Average Change Percent | -0.44335756 |
| Type Disp | Equity |
| Volume | 117,134 |
| Website | https://www.hcwbiologics.com |
| Zip | 33,025 |